UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 703

Sortiert nach

Analysing extraction uniformity from porous coffee beds using mathematical modelling and computational fluid dynamics approaches

PloS one, 2019-07, Vol.14 (7), p.e0219906-e0219906

2019

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

The New England journal of medicine, 2017-03, Vol.376 (10), p.917-927

2017

Link zum Volltext

Verfügbarkeit prüfen

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

The Lancet. Haematology, 2017-07, Vol.4 (7), p.e310-e316

2017

Link zum Volltext

Verfügbarkeit prüfen

Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1637-1647

2003

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Cancer, 2009-02, Vol.115 (3), p.551-560

2009

Link zum Volltext

Verfügbarkeit prüfen

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

Haematologica (Roma), 2009-12, Vol.94 (12), p.1669-1675

2009

Link zum Volltext

Verfügbarkeit prüfen

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Blood, 2008-04, Vol.111 (8), p.4022-4028

2008

Link zum Volltext

Verfügbarkeit prüfen

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

The Lancet. Haematology, 2019-07, Vol.6 (7), p.e375-e383

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia

Clinical cancer research, 2007-07, Vol.13 (14), p.4164-4169

2007

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study

Journal of clinical oncology, 2003-06, Vol.21 (11), p.2138-2146

2003

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

Blood, 2012-07, Vol.120 (3), p.697-698

2012

Link zum Volltext

Verfügbarkeit prüfen

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

British journal of haematology, 2002-10, Vol.119 (1), p.106-108

2002

Link zum Volltext

Verfügbarkeit prüfen

Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia

British journal of haematology, 2014-07, Vol.166 (1), p.142-145

2014

Link zum Volltext

Verfügbarkeit prüfen

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Blood, 2014-12, Vol.124 (21), p.517-517

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia

Haematologica (Roma), 2010-06, Vol.95 (6), p.922-927

2010

Link zum Volltext

Verfügbarkeit prüfen

Chronic myelogenous leukemia

Hematology, 2002, Vol.2002 (1), p.111-135

2002

Link zum Volltext

Verfügbarkeit prüfen

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia

Seminars in hematology, 2003-04, Vol.40 (2), p.26-30

2003

Link zum Volltext

Verfügbarkeit prüfen

Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study

Blood, 2002-02, Vol.99 (4), p.1150-1158

2002

Link zum Volltext

Verfügbarkeit prüfen

Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia

Blood, 2007-12, Vol.110 (13), p.4622-4623

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 703

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(655)
Mit Volltextzugriff
(632)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(520)
Life Sciences & Biomedicine
(427)
Humans
(362)
Male
(193)
Female
(190)
Biological And Medical Sciences
(162)
Medical Sciences
(123)
Middle Aged
(112)
Adult
(110)
Animals
(100)
Aged
(90)
Infectious Diseases
(66)
Immunology
(62)
Fundamental And Applied Biological Sciences. Psychology
(55)
Risk Factors
(55)
Microbiology
(53)
Science & Technology - Other Topics
(49)
Physical Sciences
(47)
Oncology
(46)
Genetics & Heredity
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(44)
Clinical Infectious Diseases
(25)
Science
(19)
The New England Journal Of Medicine
(15)
Nature
(12)
American Journal Of Human Genetics
(11)
Nature Genetics
(11)
Proceedings Of The National Academy Of Sciences - Pnas
(11)
Journal Of Clinical Oncology
(10)
Journal Of Virology
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Analysing extraction uniformity from porous coffee beds using mathematical modelling and computational fluid dynamics approaches

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia

Chronic myelogenous leukemia

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia

Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study

Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia

Suchergebnisse filtern